ClinicalTrials.gg

Program

sovleplenib

Also written as “HMPL-523” and “HMPL-523(300mg PO QD)”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Lymphoma · Anemia, Hemolytic, Autoimmune · Lymphoma, Non-Hodgkin · Thrombocytopenia, led by HUTCHMED.

Furthest: phase 3, since Aug 8, 202114 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HUTCHMED141 open or runningphase 3since Aug 8, 2021Mar 19, 2014none ahead

Also a collaborator on its studies: iqvia-pty-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2014First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT02105129 · 118 enrolled · Australia
  2. Jul 13, 2015Phase 1 study in Hematologic NeoplasmsNCT02503033 · 78 enrolled · Australia
  3. Aug 3, 2016Phase 1 study in Mature B-cell NeoplasmsNCT02857998 · 134 enrolled · China
  4. Mar 23, 2018Phase 1 study in Leukemia, Myeloid, AcuteNCT03483948 · 7 enrolled · China
  5. Dec 10, 2018Phase 1 study in Lymphoma, Non-HodgkinNCT03779113 · 69 enrolled · United States, Denmark, Finland and more
  6. May 14, 2019Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT03951623 · 45 enrolled · China
  7. Aug 8, 2021Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT05029635 · 272 enrolled · China
  8. Mar 9, 2022Early phase 1 study in Healthy SubjectNCT05318820 · 39 enrolled · China
  9. Aug 31, 2022Phase 3 study in Warm Antibody Autoimmune Hemolytic AnemiaNCT05535933 · 111 enrolled · China
  10. Oct 5, 2022Phase 1 study in RecurrenceNCT05571787 · 26 enrolled · United States
  11. Jan 31, 2023Phase 1 study in RecurrenceNCT05720767 · 28 enrolled · United States
  12. Feb 7, 2023Phase 1 study in Imumune Thrombocytopenia(ITP) Human Mass BalanceNCT05781906 · 6 enrolled · China
  13. Feb 13, 2024Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT06291415 · United States, Australia, Germany and more
  14. Nov 26, 2025Phase 1 study in HealthyNCT07348133 · 18 enrolled · China

TargetBeta

SYK →read by rule
“Tyrosine-protein kinase SYK inhibitor”ChEMBL 37, by rule

Other programs on SYK

ProgramCompanyFurthest phaseStudies
TQB3473Sino Biopharmaceuticalphase 33

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07348133Healthy · China1CompletedJan 12, 202618
NCT06291415Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Germany and more1WithdrawnApr 20260
NCT05781906Imumune Thrombocytopenia(ITP) Human Mass Balance · China1CompletedJun 1, 20236
NCT05720767Recurrence · United States1CompletedFeb 5, 202328
NCT05571787Recurrence · United States1CompletedSep 22, 202226
NCT05535933Warm Antibody Autoimmune Hemolytic Anemia · China3Active, not recruitingNov 25, 2025111
NCT05318820Healthy Subject · ChinaEarly 1CompletedJul 31, 202239
NCT05029635Purpura, Thrombocytopenic, Idiopathic · China3CompletedMay 16, 2025272
NCT03951623Purpura, Thrombocytopenic, Idiopathic · China1CompletedOct 30, 202145
NCT03779113Lymphoma, Non-Hodgkin · United States, Denmark, Finland and more1TerminatedFeb 26, 202569
NCT03483948Leukemia, Myeloid, Acute · China1TerminatedSep 9, 20197
NCT02857998Mature B-cell Neoplasms · China1CompletedJun 30, 2021134
NCT02503033Hematologic Neoplasms · Australia1UNKNOWNDec 202078
NCT02105129Arthritis, Rheumatoid · Australia1CompletedDec 2015118

How it is read

Names in the registry

  • “HMPL-523”, 13 entries
  • “HMPL-523(300mg PO QD)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.